본문으로 건너뛰기
← 뒤로

Case Report: Pseudoprogression of pancreatic acinar cell carcinoma after PD-1 blockade integrated treatment.

증례보고 1/5 보강
Frontiers in immunology 📖 저널 OA 100% 2025 Vol.16() p. 1663514
Retraction 확인
출처

Bai X, Yang D, Chen J, Liu Y, Tang H, Kong X, Liu B, Sha H, Du J

📝 환자 설명용 한 줄

Pancreatic Acinar Cell Carcinoma (PACC) is a rare subtype of pancreatic cancer, and its systematic treatment protocol is still pending for further exploration.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Bai X, Yang D, et al. (2025). Case Report: Pseudoprogression of pancreatic acinar cell carcinoma after PD-1 blockade integrated treatment.. Frontiers in immunology, 16, 1663514. https://doi.org/10.3389/fimmu.2025.1663514
MLA Bai X, et al.. "Case Report: Pseudoprogression of pancreatic acinar cell carcinoma after PD-1 blockade integrated treatment.." Frontiers in immunology, vol. 16, 2025, pp. 1663514.
PMID 41409298

Abstract

Pancreatic Acinar Cell Carcinoma (PACC) is a rare subtype of pancreatic cancer, and its systematic treatment protocol is still pending for further exploration. There have been a few reports that PACC patients benefited from immunotherapy-integrated treatment. Here, we present a metastatic PACC patient who had new hepatic lesions but lowered serum AFP and CA19-9 after 2 cycles of integrated treatment that included chemotherapy, PD-1 blockade and antiangiogenic therapy, which was later confirmed to be pseudoprogression (PsP) by pathological diagnosis. So far as we know, this is the first reported PsP case of PACC. This case highlighted the value of biopsy in distinguishing PsP from authentic tumor progression of PACC.

🏷️ 키워드 / MeSH

같은 제1저자의 인용 많은 논문 (5)

🟢 PMC 전문 열기